TY - JOUR
T1 - BRAF V600E and risk stratification of thyroid microcarcinoma
T2 - A multicenter pathological and clinical study
AU - Tallini, Giovanni
AU - De Biase, Dario
AU - Durante, Cosimo
AU - Acquaviva, Giorgia
AU - Bisceglia, Michele
AU - Bruno, Rocco
AU - Bacchi Reggiani, Maria Letizia
AU - Casadei, Gian Piero
AU - Costante, Giuseppe
AU - Cremonini, Nadia
AU - Lamartina, Livia
AU - Meringolo, Domenico
AU - Nardi, Francesco
AU - Pession, Annalisa
AU - Rhoden, Kerry J.
AU - Ronga, Giuseppe
AU - Torlontano, Massimo
AU - Verrienti, Antonella
AU - Visani, Michela
AU - Filetti, Sebastiano
PY - 2015/10/3
Y1 - 2015/10/3
N2 - Studies from single institutions have analyzed BRAF in papillary microcarcinomas, sometimes with contradictory results. Most of them have provided limited integration of histological and clinical data. To obtain a comprehensive picture of BRAF V600E-mutated microcarcinomas and to evaluate the role of BRAF testing in risk stratification we performed a retrospective multicenter analysis integrating microscopical, pathological, and clinical information. Three hundred and sixty-five samples from 300 patients treated at six medical institutions covering different geographical regions of Italy were analyzed with central review of all cases. BRAF V600E statistical analysis was conducted on 298 microcarcinomas from 264 patients after exclusion of those that did not meet the required criteria. BRAF V600E was identified in 145/298 tumors (49%) including the following subtypes: 35/37 (95%, P
AB - Studies from single institutions have analyzed BRAF in papillary microcarcinomas, sometimes with contradictory results. Most of them have provided limited integration of histological and clinical data. To obtain a comprehensive picture of BRAF V600E-mutated microcarcinomas and to evaluate the role of BRAF testing in risk stratification we performed a retrospective multicenter analysis integrating microscopical, pathological, and clinical information. Three hundred and sixty-five samples from 300 patients treated at six medical institutions covering different geographical regions of Italy were analyzed with central review of all cases. BRAF V600E statistical analysis was conducted on 298 microcarcinomas from 264 patients after exclusion of those that did not meet the required criteria. BRAF V600E was identified in 145/298 tumors (49%) including the following subtypes: 35/37 (95%, P
UR - http://www.scopus.com/inward/record.url?scp=84942985527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942985527&partnerID=8YFLogxK
U2 - 10.1038/modpathol.2015.92
DO - 10.1038/modpathol.2015.92
M3 - Article
C2 - 26271724
AN - SCOPUS:84942985527
VL - 28
SP - 1343
EP - 1359
JO - Modern Pathology
JF - Modern Pathology
SN - 0893-3952
IS - 10
ER -